Pomegra
Oklo receives U.S. Department of Energy clearance for its Groves Isotope Test Reactor, unlocking fuel loading and first criticality for the nuclear energy startup.
- DOE granted Oklo startup authorization for the Groves reactor on July 23, 2026, clearing fuel loading and first criticality.
- Oklo reached this milestone in just over 10 months from groundbreaking, an unprecedented pace for a nuclear project.
- OKLO stock rose as much as 4.92% to $54.90 following the announcement.
Lead
Oklo Inc. received U.S. Department of Energy startup authorization for its Groves Isotope Test Reactor on July 23, 2026, completing the agency's full authorization process and opening the path to fuel loading, startup testing, and first criticality. The clearance marks the most consequential regulatory milestone yet for one of the United States' leading nuclear energy startups, arriving just over 10 months after the reactor facility broke ground — a timeline that has no precedent in modern U.S. nuclear development.What Happened
The DOE's authorization — the final stage of the agency's internal review sequence — permits Oklo to receive and load nuclear fuel into the Groves reactor and begin formal startup testing. First criticality, the point at which a reactor achieves a self-sustaining nuclear chain reaction, is targeted for July 2026.
The Groves facility is a low-power test reactor sited on privately owned land in Texas and is fueled entirely from commercially sourced nuclear material. It is the first advanced reactor to receive a Documented Safety Analysis approval under those conditions, setting a structural precedent for how future commercial reactors in the United States may be permitted and built.
During the 10-month sprint from groundbreaking to Groves reactor authorization, Oklo constructed the reactor facility, established a qualified operating organization, procured fuel and major equipment from commercial vendors, and satisfied each stage of DOE's authorization sequence.
Strategic Context
The Groves reactor is designed to demonstrate the reactor design, build, and operational capabilities needed to support Oklo's broader commercial strategy: domestic production of critical isotopes. Applications span cancer diagnosis and treatment, advanced manufacturing, scientific research, space exploration, and national security — markets where U.S. supply chains currently depend heavily on foreign sources.
The project's velocity reflects the Trump Administration's Reactor Pilot Program (RPP), enacted by executive order in 2025 to accelerate nuclear deployment. The RPP instructs the Nuclear Regulatory Commission to create an expedited approval pathway for reactors that have been safely tested by the DOE, with an 18-month deadline to evaluate and approve new construction and operating licenses. Groves is among the first projects to navigate that structure in practice.
Market Reaction
OKLO stock climbed to $54.90, a gain of 4.92%, on the day of the announcement, extending a pattern of positive momentum around each regulatory approval. The stock had risen roughly 4% in the five trading days following an earlier DOE safety analysis clearance on July 1. The consensus analyst price target stands at $84.10, implying approximately 62% upside from pre-announcement levels.Outlook
With DOE startup authorization secured, Oklo moves to fuel loading as its immediate next step. First criticality would validate the reactor's design, operating protocols, and commercial supply chain — data that underpins the company's applications for full commercial-scale isotope production facilities and its longer-term pipeline of power-generating reactors. Progress at Groves is also expected to inform NRC's expedited review track under the RPP, with implications for the broader nuclear energy startup ecosystem seeking to follow a similar regulatory path.
Mentioned tickers: OKLOBreaking }}
